Aptevo Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.3M
- Price
- $2.68
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.90%
- Volume
- 55.3K
About
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Quick stats
Shares outstanding1.2M
Computed float1.2M
Float / shares94.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001671584
AI Summary
AI-generated1/9
standardbullishclinical trial
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Aptevo reported updated Phase 1b/2 data for its lead candidate mipletamig in frontline acute myeloid leukemia, demonstrating an 81% remission rate and 87% clinical benefit rate across evaluable patients.
The company advanced its corporate strategy by appointing Dr. Mary J. Janatpour as CSO, securing a $1.5M non-dilutive grant for APVO451, and forming a 50/50 radiopharmaceutical collaboration with Niowave that included an equity investment.
As of June 30, 2026, Aptevo held $9.8 million in cash and raised $0.6 million through equity purchase agreements during the quarter.
Red flags
- Low cash position of $9.8 million raises near-term financing viability concerns